Open AccessClinical characteristics, laboratory parameters and outcomes of COVID‐19 in cancer and non‐cancer patients from a tertiary Cancer Centre in India
Author(s) -
Mirgh Sumeet P.,
Gokarn Anant,
Rajendra Akhil,
More Ashwini,
Kamtalwar Sujit,
Katti Kritika S.,
Singh Anuj,
Goli Vasu Babu,
Ravind Rahul,
Madala Ravikrishna,
Kakoti Sangeeta,
Maitre Priyamvada,
Punatar Sachin,
Chichra Akanksha,
Patil Amar,
Trivedi Bhakti,
Joshi Amit,
Patkar Nikhil,
Tembhare Prashant,
Khanka Twinkle,
Rajpal Sweta,
Chatterjee Gaurav,
Kannan Sadhana,
Subramanian P.G.,
Murthy Vedang,
Shetty Nitin,
Chavan Preeti,
Bhat Vivek,
Nair Sudhir,
Khattry Navin,
Gupta Sudeep
Publication year - 2021
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.4379
Subject(s) - medicine , interquartile range , cancer , retrospective cohort study , odds ratio , covid-19 , cohort , disease , infectious disease (medical specialty)
Background There is paucity of data regarding clinical characteristics, laboratory parameters and outcomes of coronavirus disease (COVID‐19) in cancer versus non‐cancer patients, particularly from India. Materials and Methods This was an observational, single‐centre, retrospective analysis of patients with laboratory‐confirmed COVID‐19 hospitalised in our institution between 22 May 2020 and 1 December 2020. We compared baseline clinical characteristics, laboratory parameters and outcomes of COVID‐19 (overall mortality, time to discharge) between cancer and non‐cancer patients. Results A total of 200 COVID‐19 infection episodes were analysed of which 109 (54.5%) were patients with cancer and 91 (45.5%) were patients without cancer. The median age was 43 (interquartile range [IQR]:32–57), 51 (IQR: 33–62) and 38 (IQR: 31.5–49.3) years; of whole cohort, cancer and non‐cancer patients, respectively. Comparison of outcomes showed that oxygen requirement (31.2% [95% CI: 22.6–40.7] vs. 17.6% [95% CI: 10.4–26.9]; p = 0.03), median time to discharge (11 days [IQR: 6.75–16] vs. 6 days [IQR: 3–9.75]; p < 0.001) and mortality (10.0% [95% CI: 5.2–17.3] vs. 1.1% [95% CI: 0.03–5.9]; p = 0.017) were significantly higher in patients with cancer. In univariable analysis, factors associated with higher mortality in the whole cohort included diagnosis of cancer (10.1% vs. 1.1%; p = 0.027; odds ratio [OR]: 7.04), age ≥60 (17.4% vs. 2.6%; p = 0.001; OR: 7.38), oxygen requirement (22% vs. 0.6%; p < 0.001; OR: 29.01), chest infiltrates (19.2% vs. 1.4%; p < 0.001; OR: 22.65), baseline absolute lymphocyte count <1 × 10 9 /L (10.8% vs. 1.9%; p = 0.023; OR:5.1), C‐reactive protein >1 mg% (12.8% vs. 0%; p = 0.027; OR: 24.69), serum procalcitonin >0.05 ng/ml (22.65% vs. 0%; p = 0.004; OR: 4.49) and interleukin‐6 >6 pg/ml (10.8% vs. 1.3%; p = 0.036; OR: 3.08). In multivariable logistic regression, factors significantly associated with mortality were oxygen requirement ( p = 0.005; OR: 13.11) and high baseline procalcitonin level ( p = 0.014; OR: 37.6). Conclusion Cancer patients with COVID‐19 have higher mortality and require longer hospital stay. High procalcitonin levels and oxygen requirement during admission are other factors that affect outcomes adversely.